Literature DB >> 16585474

Perceived loss of memory ability and cerebral metabolic decline in persons with the apolipoprotein E-IV genetic risk for Alzheimer disease.

Linda Ercoli1, Prabha Siddarth, Sung-Cheng Huang, Karen Miller, Susan Y Bookheimer, Benjamin C Wright, Michael E Phelps, Gary Small.   

Abstract

CONTEXT: Concerns about age-related memory loss are greater in persons who have the apolipoprotein E-IV (APOE4) genetic risk for Alzheimer disease, but the correlation between the degree of concerns and future cerebral metabolic decline is unknown.
OBJECTIVE: To investigate whether the degree of self-perceived memory loss is associated with regional cerebral metabolic decline.
DESIGN: Longitudinal study.
SETTING: Aging and Memory Research Center, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles. PARTICIPANTS: Thirty right-handed, cognitively intact, middle-aged and older adults (age range, 50-82 years) with age-associated memory complaints, 14 of whom were carriers of the apolipoprotein E-IV allele, were recruited for longitudinal study. MAIN OUTCOME MEASURES: At baseline, we administered a standardized neuropsychological battery and assessed self-appraisal of memory functioning using the Memory Functioning Questionnaire, which yields 4 factor scores indicating frequency of forgetting, seriousness of forgetting, retrospective functioning, and mnemonics use. Regional cerebral glucose metabolism was determined using fluorodeoxyglucose F18-positron emission tomography at baseline and after 2 years.
RESULTS: At baseline, APOE4 carriers and noncarriers did not differ significantly on objective memory measures or on Memory Functioning Questionnaire factor scores. However, the factor score for frequency of forgetting significantly correlated with global cerebral metabolic decline in all subjects regardless of APOE4 genetic risk (P = .01). By contrast, the factor score for mnemonics use significantly correlated with metabolic decline in the temporal regions in APOE4 carriers but not in noncarriers (P = .03).
CONCLUSIONS: The degree of perceived memory loss correlates with subsequent global cerebral metabolic decline for APOE4 carriers and noncarriers; hence, memory complaints may reflect underlying cerebral metabolic changes. Compensatory strategies, as reflected by more frequent mnemonics use in APOE4 carriers, may reflect underlying metabolic changes in the brain regions associated with prodromal Alzheimer disease. Self-reported mnemonics use may be helpful in identifying persons for clinical monitoring.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16585474     DOI: 10.1001/archpsyc.63.4.442

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  10 in total

1.  Measuring cognitive complaints in breast cancer survivors: psychometric properties of the patient's assessment of own functioning inventory.

Authors:  Kathleen Van Dyk; Patricia A Ganz; Linda Ercoli; Laura Petersen; Catherine M Crespi
Journal:  Support Care Cancer       Date:  2016-07-19       Impact factor: 3.603

2.  Family history of Alzheimer's disease and hippocampal structure in healthy people.

Authors:  Markus Donix; Alison C Burggren; Nanthia A Suthana; Prabha Siddarth; Arne D Ekstrom; Allison K Krupa; Michael Jones; Laurel Martin-Harris; Linda M Ercoli; Karen J Miller; Gary W Small; Susan Y Bookheimer
Journal:  Am J Psychiatry       Date:  2010-08-04       Impact factor: 18.112

3.  Self-reported memory impairment and brain PET of amyloid and tau in middle-aged and older adults without dementia.

Authors:  David A Merrill; Prabha Siddarth; Nathan Y Saito; Linda M Ercoli; Alison C Burggren; Vladimir Kepe; Helen Lavretsky; Karen J Miller; Jeanne Kim; S C Huang; Susan Y Bookheimer; Jorge R Barrio; Gary W Small
Journal:  Int Psychogeriatr       Date:  2012-02-16       Impact factor: 3.878

4.  Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals.

Authors:  Audrey Perrotin; Elizabeth C Mormino; Cindee M Madison; Amynta O Hayenga; William J Jagust
Journal:  Arch Neurol       Date:  2012-02

5.  Memory complaints are related to Alzheimer disease pathology in older persons.

Authors:  L L Barnes; J A Schneider; P A Boyle; J L Bienias; D A Bennett
Journal:  Neurology       Date:  2006-11-14       Impact factor: 9.910

6.  Assessing the progression of mild cognitive impairment to Alzheimer's disease: current trends and future directions.

Authors:  Larry G Brooks; David A Loewenstein
Journal:  Alzheimers Res Ther       Date:  2010-09-29       Impact factor: 6.982

7.  Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints.

Authors:  Lisa Mosconi; Susan De Santi; Miroslaw Brys; Wai H Tsui; Elizabeth Pirraglia; Lidia Glodzik-Sobanska; Kenneth E Rich; Remigius Switalski; Pankaj D Mehta; Domenico Pratico; Ray Zinkowski; Kay Blennow; Mony J de Leon
Journal:  Biol Psychiatry       Date:  2007-08-27       Impact factor: 13.382

8.  Psychological well-being and regional brain amyloid and tau in mild cognitive impairment.

Authors:  Stephen T Chen; Prabha Siddarth; Nathan Y Saito; Flori Rueda; Taylor Haight; Linda M Ercoli; Karen J Miller; Helen Lavretsky; Jorge R Barrio; Susan Y Bookheimer; Gary W Small; David A Merrill
Journal:  Am J Geriatr Psychiatry       Date:  2013-03-26       Impact factor: 4.105

9.  Ageing as a mindset: a study protocol to rejuvenate older adults with a counterclockwise psychological intervention.

Authors:  Francesco Pagnini; Cesare Cavalera; Eleonora Volpato; Benedetta Comazzi; Francesco Vailati Riboni; Chiara Valota; Katherine Bercovitz; Enrico Molinari; Paolo Banfi; Deborah Phillips; Ellen Langer
Journal:  BMJ Open       Date:  2019-07-09       Impact factor: 2.692

10.  Modifiable risk factors for Alzheimer disease and subjective memory impairment across age groups.

Authors:  Stephen T Chen; Prabha Siddarth; Linda M Ercoli; David A Merrill; Fernando Torres-Gil; Gary W Small
Journal:  PLoS One       Date:  2014-06-04       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.